17-β-estradiol potentiates the neurotrophic and neuroprotective effects mediated by the dopamine D3/acetylcholine nicotinic receptor heteromer in dopaminergic neurons
Open Access
- 29 May 2024
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 976, 176678
Abstract
No abstract availableKeywords
Funding Information
- University of Brescia
This publication has 70 references indexed in Scilit:
- Recent Advances in Dopamine D3 Receptor Heterodimers: Focus on Dopamine D3 and D1 Receptor–Receptor Interaction and Striatal Function2022
- Sex differences in LRRK2 G2019S and idiopathic Parkinson's DiseaseAnnals of Clinical and Translational Neurology, 2017
- Formulations of hormone therapy and risk of Parkinson's diseaseMovement Disorders, 2014
- The complexities of hormonal influences and risk of Parkinson's diseaseMovement Disorders, 2014
- Effect of Different Doses of Estrogen on the Nigrostriatal Dopaminergic System in Two 6-Hydroxydopamine-Induced Lesion Models of Parkinson’s DiseaseNeurochemical Research, 2011
- Reproductive factors, exogenous estrogen use, and risk of Parkinson's diseaseMovement Disorders, 2009
- Regulation of the phosphoinositide‐3 kinase and mitogen‐activated protein kinase signaling pathways by progesterone and its reduced metabolites in the rat brainJournal of Neuroscience Research, 2008
- Progesterone increases brain‐derived neuroptrophic factor expression and protects against glutamate toxicity in a mitogen‐activated protein kinase‐ and phosphoinositide‐3 kinase‐dependent manner in cerebral cortical explantsJournal of Neuroscience Research, 2007
- Gender and the Parkinson’s disease phenotypeJournal of Neurology, 2005
- Stereospecific prevention by 17?-estradiol of MPTP-induced dopamine depletion in miceSynapse, 2000